SynuSight Biotech has licensed 18F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment ...
Morning Overview on MSN
New imaging breakthrough makes cancer cells light up on cue
Cancer imaging is entering a phase where malignant cells no longer hide in murky grayscale but flare into view with surgical precision. Across operating rooms, scanners, and even blood tests, ...
Abstract: Contrast enhancement is widely used in computed tomogra-phy (CT) scans, where radiocontrast agents circulate through the bloodstream and accumulate in the vasculature, creating visual ...
Software-based quantitative assessment of ablation margins: a new standard for liver tumour ablation
Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For a long time, thermal ...
Purpose: To construct diagnostic models that distinguish renal oncocytoma (RO) from chromophobe renal cell carcinoma (CRCC) using intratumoral and peritumoral radiomic features from the ...
Results of the Phase I clinical trial, presented at the bi-annual Contrast Media Research symposium in Oslo, Norway, conclude that this novel macrocyclic manganese-based contrast agent was well ...
Synchrotron radiation propagation-based phase-contrast micro-computed tomography (SR μ CT) has been used increasingly for detailed characterization of tissue specimens, alternative to classical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback